Cognitive Drug Research Shows Promising Improvement in Parkinson's Patients
Results from a new study published in the December issue of New England Journal of Medicine, show that the Cognitive Drug Research (CDR) Power
of Attention composite score identified a marked and highly significant (p=0.009) improvement over placebo in Parkinson's disease patients with
"Rivastigmine for Dementia Associated with Parkinson's Disease", is the first large-scale, prospective, placebo-controlled trial to
demonstrate statistically significant cognitive benefits on a range of measures in PDD patients.
"We're very proud to have been involved in this large novel study," said Professor Keith Wesnes, founder of CDR.
"The range of improvements to various aspects of attention was large and would have a clear everyday benefit to the patients. This trial is
also extremely important as it indicates that certain treatments for Alzheimer's disease can also be applied to PDD patients," he went on to
In a follow-up editorial published in the same issue, Daniel Z. Press, M.D. commented that one of the primary measures in the study, the
Alzheimer's Disease Assessment Scale, may have underestimated the clinical improvement due to its lack of sensitivity to the deficits in PDD
Dr. Press also remarked that the CDR Power of Attention composite was one of the measures that would be more sensitive and wrote " ... did
show a more substantial improvement".
In addition, a study published in The Lancet in 2000 also showed improvements to CDR attention measures when rivastigmine was administered to
patients with Dementia with Lewy Bodies.
The CDR System is used to assess specific areas of cognitive function that include attention, working memory and episodic secondary
The system is fully automated and the computer controls stimuli presentation, automatically captures data, and prepares the data for
Most importantly, the test subject is only required to interact with a specially designed response box and does not require any prior computer
knowledge. The CDR Attention Test Battery takes between 5 and 7 minutes to perform.
About Cognitive Drug Research, Ltd.
Founded in 1986, Cognitive Drug Research Ltd. (CDR) is the world's leading provider of innovative cognitive function assessment technology and
services to the pharmaceutical industry.
CDR combines innovative technology and validated psychometric tests to definitively measure the effects of pharmaceuticals on the mental
efficiency of volunteers and patients in clinical trials.
CDR is a privately held company with headquarters in the Goring-on-Thames, U.K. and a sales office in New Jersey, U.S.A. Additional
information about CDR can be found by visiting the company's website on http://www.cdr.org.uk or via email at
firstname.lastname@example.org. CDR can also be reached on +44 (0) 1491 878700